NBIX Form 4 reports multiple insider transactions
Boyer David W. reported multiple insider transaction types in a Form 4 filing for NBIX.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Boyer David W. reported multiple insider transaction types in a Form 4 filing for NBIX. The filing lists transactions totaling 64,637 shares at a weighted average price of $124.01 per share. Following the reported transactions, holdings were 3,083 shares.
Insider Trade Summary
4,952 shares exercised/converted
Exercise
13 txns
Insider
Boyer David W.
Role
Chief Corp. Affairs Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Unit | 1,541 | $0.00 | $0.00 |
| Exercise | Restricted Stock Unit | 1,811 | $0.00 | $0.00 |
| Grant/Award | Stock Option | 31,234 | $0.00 | $0.00 |
| Grant/Award | Restricted Stock Unit | 5,479 | $0.00 | $0.00 |
| Exercise | Common Stock | 1,541 | $0.00 | $0.00 |
| Exercise Price or Tax Liability | Common Stock | 832 | $124.12 | $103K |
| Exercise | Common Stock | 1,811 | $0.00 | $0.00 |
| Exercise Price or Tax Liability | Common Stock | 978 | $124.12 | $121K |
| Grant/Award | Common Stock | 9,968 | $0.00 | $0.00 |
| Exercise Price or Tax Liability | Common Stock | 5,378 | $124.12 | $668K |
| Exercise | Restricted Stock Unit | 1,600 | $0.00 | $0.00 |
| Exercise | Common Stock | 1,600 | $0.00 | $0.00 |
| Exercise Price or Tax Liability | Common Stock | 864 | $123.10 | $106K |
Holdings After Transaction:
Restricted Stock Unit — 15,175 contracts (Direct);
Stock Option — 31,234 contracts (Direct);
Common Stock — 11,581 shares (Direct)
Footnotes (8)
- F1. Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold.
- F2. On May 19, 2023, the Reporting Person was granted PRSUs representing the right to receive shares of the Issuer's common stock based upon the achievement of specified performance metrics over the three-year performance period ending on December 31, 2025. Effective February 13, 2026, the achievement of the applicable performance metrics and the resulting payout level were certified, and, as a result of such certification, the PRSUs vested at 125% of the target number of shares subject to the award.
- F3. Each RSU represents a contingent right to receive one share of the Issuer's common stock .
- F4. This RSU was granted to the Reporting Person on February 12, 2025. In accordance with the terms of the RSU, the award vested as to 1,600 shares on February 12, 2026, and will vest as to 1,600 shares on February 12, 2027, 1,600 shares on February 12, 2028, and 1,601 shares on February 12, 2029, subject to the terms and conditions of the award.
- F5. This RSU was granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 1,541 shares on February 13, 2025, vested as to 1,541 shares on February 13, 2026, and will vest as to 1,541 shares on February 13, 2027, and 1,542 shares on February 13, 2028, subject to the terms and conditions of the award.
- F6. This RSU was granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 1,811 shares on February 13, 2024, vested as to 1,811 shares on February 13, 2025, vested as to 1,811 shares on February 13, 2026, and will vest as to 1,812 shares on February 13, 2027, subject to the terms and conditions of the award.
- F7. Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2026 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.
- F8. The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2027, February 13, 2028, February 13, 2029, and February 13, 2030.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did NBIX officer David W. Boyer report?
David W. Boyer reported RSU conversions into common stock, tax-related share withholdings, a stock option grant for 31,234 shares at a $124.12 exercise price, and a grant of 5,479 restricted stock units. These transactions reflect equity compensation, not open-market stock purchases or sales.
What stock option grant did NBIX award to David W. Boyer?
He received a stock option covering 31,234 shares of Neurocrine Biosciences common stock at a $124.12 exercise price. One forty-eighth of the option vests and becomes exercisable on March 13, 2026, with an additional one forty-eighth vesting monthly thereafter until fully vested by 2030.
How do the new restricted stock units for NBIX’s David W. Boyer vest?
He was granted 5,479 restricted stock units that vest annually. One quarter of the units vests on each of February 13, 2027, February 13, 2028, February 13, 2029, and February 13, 2030, subject to the award’s terms and continued service conditions specified in the grant.
What performance-based RSU outcome did NBIX disclose for David W. Boyer?
Performance RSUs granted on May 19, 2023 vested based on metrics over a period ending December 31, 2025. On February 13, 2026, Neurocrine certified achievement of those metrics, resulting in the PRSUs vesting at 125% of the target number of shares under the award.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates